ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)
| dc.rights.license | open | en_US |
| dc.contributor.author | FLEURY, H. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CALDATO, Sabrina | |
| dc.contributor.author | RECORDON-PINSON, P. | |
| dc.contributor.author | THEBAULT, P. | |
| dc.contributor.author | GUIDICELLI, G. L. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | HESSAMFAR, Mojgan | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MORLAT, Philippe | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BONNET, Fabrice | |
| dc.contributor.author | VISENTIN, J. | |
| dc.date.accessioned | 2021-01-25T11:29:21Z | |
| dc.date.available | 2021-01-25T11:29:21Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1999-4915 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/25982 | |
| dc.description.abstractEn | We proposed a new HIV-1 therapeutic vaccine based on conserved cytotoxic T lymphocyte (CTL) epitopes of archived HIV-1 DNA according to their affinity to the dominant HLA-A and -B alleles of the population investigated. Our proposal (Hla Fitted VAC, HFVAC) was composed of 15 peptides originating from the RT, gag and nef parts of proviral DNA. Our aim was to investigate baseline immune reactivity to the vaccine in HIV-1 chronically infected patients at success of antiretroviral therapy (ART) who would be eligible for a therapeutic vaccine. Forty-one patients were tested. Most of them had been infected with HIV-1 subtype B and all had been receiving successful ART for 2 to 20 years. The predominant HLA-A and -B alleles were those of a Caucasian population. ELISPOT was carried out using the HFVAC peptides. In 22 patients, the PD-1 marker was investigated on CD4+ and CD8+ T cells by flow cytometry in order to evaluate global T cell exhaustion. ELISPOT positivity was 65% overall and 69% in patients exhibiting at least one HLA allele fitting with HFVAC. The percentages of CD4+ and CD8+ T cells expressing PD-1 were high (median values 23.70 and 32.60, respectively), but did not seem to be associated with an impairment of the immune response investigated in vitro. In conclusion, reactivity to HFVAC was high in this ART-treated population with dominant HLA alleles, despite potential cellular exhaustion associated with the PD-1 marker. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject | IDLIC | |
| dc.subject | MORPH3Eus | |
| dc.title.en | ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study) | |
| dc.title.alternative | Viruses | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/v12111256 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33167335 | en_US |
| bordeaux.journal | Viruses | en_US |
| bordeaux.volume | 12 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 11 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | IDLIC | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03120135 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-01-25T11:29:25Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Viruses&rft.date=2020&rft.volume=12&rft.issue=11&rft.eissn=1999-4915&rft.issn=1999-4915&rft.au=FLEURY,%20H.&CALDATO,%20Sabrina&RECORDON-PINSON,%20P.&THEBAULT,%20P.&GUIDICELLI,%20G.%20L.&rft.genre=article |
